<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00507728</url>
  </required_header>
  <id_info>
    <org_study_id>2003-1024</org_study_id>
    <secondary_id>1R01DA017073</secondary_id>
    <secondary_id>NCI-2012-02108</secondary_id>
    <nct_id>NCT00507728</nct_id>
  </id_info>
  <brief_title>Pharmacogenetics, Emotional Reactivity and Smoking</brief_title>
  <official_title>Pharmacogenetics, Emotional Reactivity and Smoking</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goals of this placebo-controlled randomized clinical trial were to evaluate the&#xD;
      differences in emotional reactivity (peak startle response to affective stimuli) during a&#xD;
      cessation attempt among smokers treated with bupropion, varenicline, or placebo, and to&#xD;
      determine if these differences were moderated by genotype.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bupropion and Varenicline are smoking cessation aids that may help people to quit smoking.&#xD;
&#xD;
      During the orientation visit, the study will be explained to you and you will be given an&#xD;
      opportunity to ask, and have answered, any questions you may have. You will also be asked to&#xD;
      give a buccal (cheek cell) sample for genetic analysis. This session will last about 1.5&#xD;
      hours.&#xD;
&#xD;
      During the screening visit, you will be asked questions about your health, medication use,&#xD;
      smoking history, and tobacco use. You will be asked about any current or past feelings of&#xD;
      depression. Also, a small blood sample will be drawn (about 2 tablespoons) from your upper&#xD;
      arm for a liver and kidney function test and a saliva sample will be collected to measure&#xD;
      whether you are smoking. Women who are able to have children must have a negative urine&#xD;
      pregnancy test. This session will last about 2.5 hours.&#xD;
&#xD;
      If you are eligible to take part in the study, you will be randomly assigned (as in the toss&#xD;
      of a coin) to one of three treatment groups. Participants in the first group will receive&#xD;
      Bupropion. Participants in the second group will receive Varenicline. Participants in the&#xD;
      third group will receive a placebo. A placebo is a substance that looks like the study drug&#xD;
      but which has no active ingredients. You will have an equal chance of being assigned to the&#xD;
      Bupropion, Varenicline, or placebo treatment group. Neither you nor your counselor will know&#xD;
      to which group you were assigned.&#xD;
&#xD;
      All participants will take study pills (either Bupropion, Varenicline, or placebo) by mouth&#xD;
      for 12 weeks. The dose of study medication may or may not change during the study. You will&#xD;
      be responsible for returning any unused, used, or partly used study medication bottles to a&#xD;
      study staff member.&#xD;
&#xD;
      All participants will receive smoking cessation counseling to help them quit smoking, in the&#xD;
      form of both in-person and telephone counseling sessions. Some of the counseling sessions may&#xD;
      be videotaped or audio-taped. The videotapes will be used to help the investigators make sure&#xD;
      that the counselors are following the correct procedures and will be erased within one year&#xD;
      following your completion of the study. No one but the study investigators or those delegated&#xD;
      by the study investigators will be allowed to view the tapes and the identity of the&#xD;
      participants will be kept strictly confidential. Staff that may be given permission to view&#xD;
      the tapes include project staff, consultants that review and rate how well the study&#xD;
      counselors follow guidelines, and/or consultants that review how well the assessments are&#xD;
      given.&#xD;
&#xD;
      You will need to come to the Behavioral Science Research Clinic at M. D. Anderson for 9&#xD;
      clinic visits over an 8-month period. You will receive 5 telephone calls from the study staff&#xD;
      (while in treatment and during follow-up) to check on your progress in quitting smoking.&#xD;
&#xD;
      You will complete your first lab evaluation session (baseline) before any treatment begins&#xD;
      (while you are still smoking). Immediately after the baseline lab session (on the same day),&#xD;
      you will begin to receive counseling to quit smoking. You will begin taking one of the 3&#xD;
      study medications (Bupropion, Varenicline, or placebo) the next morning.&#xD;
&#xD;
      There will be 3 lab sessions, during which you will be asked to complete questionnaires about&#xD;
      your mood and feelings (about 30 minutes total). Also, you will give a breath sample by&#xD;
      blowing air into a small tube. This sample shows how much you have smoked. In each session&#xD;
      you will be asked to watch slides and listen to a series of tones through earphones. The&#xD;
      slides will include pictures of people, nature scenes, and artwork. Slides showing victims of&#xD;
      car crashes, medical procedures, and nude people will also be shown. You will be shown&#xD;
      examples of these slides before beginning the procedure and given the opportunity to withdraw&#xD;
      from the study. During the lab sessions, your heart rate, brain electrical activity (EEG),&#xD;
      skin sweating, and muscle tension will be monitored. To do this, small sensors will be placed&#xD;
      on the fingers, arms, scalp and face. You should not drink more than 2 cups of coffee or&#xD;
      other caffeine drinks at least 2.5 hours before each session.&#xD;
&#xD;
      During the first counseling visit, you will set a quit date for stopping smoking about 2&#xD;
      weeks after starting your study medication. You are asked not to quit smoking before the set&#xD;
      quit date. After your quit date, you are asked to stay smoke free. You are asked to attend&#xD;
      all your sessions whether you are smoking or not. All participants will receive smoking&#xD;
      cessation counseling in the form of both in-person and telephone counseling sessions. The&#xD;
      purpose of these visits will be to prepare you for quitting and to check the effects of the&#xD;
      study medication on your attempt to stop smoking.&#xD;
&#xD;
      At each of your clinic visits, your blood pressure will be taken and you will be asked to&#xD;
      blow air through a carbon monoxide (CO) measuring device. CO is a gas that is found in higher&#xD;
      levels among cigarette smokers. At several visits you will be asked to provide a saliva&#xD;
      sample to check for cotinine, a chemical produced by the breakdown of nicotine during&#xD;
      smoking. You will be asked to give a saliva sample in a collection tube. Like the CO test,&#xD;
      this test will help researchers measure how much you are smoking.&#xD;
&#xD;
      At your visits you will be asked questions about your smoking behavior. You will also be&#xD;
      asked questions about your health and medical condition, and about any medications you are&#xD;
      taking. You will be asked to complete a daily diary on cigarette smoking and drug dosing.&#xD;
&#xD;
      You will also be asked to mail saliva samples back to the clinic at least two times after&#xD;
      stopping the medication. This will allow researchers to check on your smoking status.&#xD;
&#xD;
      Your total participation in this study will last about 8 months. This will include a 3-month&#xD;
      and 6-month follow-up visit after your scheduled quit date. If the study staff is not able to&#xD;
      reach you by phone, mail, or the information provided by your contacts, they may try to&#xD;
      locate you through telephone directory assistance (411) or internet search sources (for&#xD;
      example, Google or Yahoo!), which use information from the public domain (meaning everyone&#xD;
      has access to it). If the study staff is still unable to find you, they may use a locator&#xD;
      service such as Transunion or the National Change of Address (NCOA) database maintained by&#xD;
      the United States Postal Service, as a last resort. Transunion uses magazine subscriptions&#xD;
      and credit applications to find new addresses, and the NCOA uses the Change of Address cards&#xD;
      filed with the post office when a person moves and requests their mail be forwarded to a new&#xD;
      address. If the study staff has to use either of these services, they would only disclose&#xD;
      your name and last known address.&#xD;
&#xD;
      At the end of the study, you will be able to ask additional questions about the results of&#xD;
      the study and about procedures you have experienced during the study. Additionally, you will&#xD;
      be able to sign up to receive a copy of the paper that will be written at the completion of&#xD;
      the study.&#xD;
&#xD;
      This is an investigational study. Up to 375 smokers will take part in this study. All will be&#xD;
      enrolled at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 8, 2005</start_date>
  <completion_date type="Actual">December 18, 2019</completion_date>
  <primary_completion_date type="Actual">December 18, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Emotional Reactivity By Pharmacotherapy</measure>
    <time_frame>Baseline to 1 month</time_frame>
    <description>Emotional reactivity measured by the peak eye blink electromyography (EMG) of the orbicularis oculi (ORB) muscle responses to acoustic startle probe delivered during the presentation of emotionally valent stimuli (pleasant, unpleasant, neutral, and smoking-related pictures). A single value was estimated by averaging within the specific time interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Emotional Reactivity By Pharmacotherapy Moderated by DRD2 A1 Allele</measure>
    <time_frame>Baseline to 1 month</time_frame>
    <description>The emotional reactivity (ORB EMG) of smokers during cessation will be moderated by genotype. A single value was estimated by averaging within the specific time interval. During a quit attempt, smokers were evaluated on how they react to smoking related cues. An interaction term was then formed by the reactivity to smoking stimulus and genotype.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Smoking Abstinence at 3 Months</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Smoking Abstinence at 3 Months by DRD2 A1 Allele</measure>
    <time_frame>Baseline to 3 Month</time_frame>
    <description>Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Smoking Abstinence at 6 Months</measure>
    <time_frame>Abstinence at 6 Months ( the effects shown are the increase/decrease in probability of abstinence for 1 unit increase in the predictor)</time_frame>
    <description>Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abstinence at 6 Months by DRD2 A1 Allele</measure>
    <time_frame>Baseline to 6 Month ( the effects shown are the increase/decrease in probability of abstinence for 1 unit increase in the predictor)</time_frame>
    <description>Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of Nicotine Withdrawal Using the Wisconsin Smoking Withdrawal Scale (WSWS)</measure>
    <time_frame>Baseline to 8 months</time_frame>
    <description>Symptoms of nicotine withdrawal measured using Wisconsin Smoking Withdrawal Scale (WSWS). The Wisconsin Withdrawal Scale (WSWS) contains 7 factors: Anger, Anxiety, Sadness, Concentration, Craving, Sleep, and Hunger. WSWS consists of 28 items that are scored on a 5-point Likert type scale (0 = strongly disagree, 4 = strongly agree). A single value was estimated by averaging within the specific time interval. Higher values represent worse outcome. The average value was estimated from Baseline to 8 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of Nicotine Withdrawal and Negative Affect Using Positive and Negative Affect Scale (PANAS)</measure>
    <time_frame>Baseline to 8 months</time_frame>
    <description>Symptoms of nicotine withdrawal and negative affect were measured using the Positive and Negative Affect Scale (PANAS). The Positive and Negative Affect Schedule (PANAS) is a self-report questionnaire to measure both positive and negative affect. Each item is rated on a 5-point scale of 1 (not at all) to 5 (very much). Scores can range from 10-50 for both the Positive and Negative Affect with the lower scores representing lower levels of Positive/Negative Affect and higher scores representing higher levels of Positive/Negative Affect. The average value was estimated from Baseline to 8 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of Depression Using the Center for Epidemiologic Studies Depression Scale (CES-D)</measure>
    <time_frame>Baseline to 8 months</time_frame>
    <description>Symptoms of nicotine withdrawal measured using Center for Epidemiologic Studies Depression Scale (CES-D). Center of Epidemiologic Studies Depression Scale (CESD) a 20-item measure that asks caregivers to rate how often over the past week they experienced symptoms associated with depression, such as restless sleep, poor appetite, and feeling lonely. Response options range from 0 to 3 for each item (0 = Rarely or None of the Time, 1 = Some or Little of the Time, 2 = Moderately or Much of the time, 3 = Most or Almost All the Time). Scores range from 0 to 60, with high scores indicating greater depressive symptoms. The average value was estimated from Baseline to 8 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of Smoking Satisfaction and Psychological Reward Using the Modified Cigarette Evaluation Questionnaire (mCEQ) Subscales</measure>
    <time_frame>Baseline to 8 months</time_frame>
    <description>Modified Cigarette Evaluation Questionnaire (mCEQ). mCEQ Smoking satisfaction: range (1-21); mCEQ Psychological Reward: range(1-35); mCEQ Aversion: range (1-14); mCEQ Enjoyment of Resp.Tract Sens: range (1-7); mCEQ Craving Reduction: range (1-7). For all scales of mCEQ higher scores indicate worse outcomes (greater intensity of smoking effect). Scores of mCEQ Smoking satisfaction, mCEQ psychological reward and mCEQ aversion were summed to create the subscales. mCEQ Enjoyment of Resp Tract Sens and mCEQ Craving Reduction were single items.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Conductance Response</measure>
    <time_frame>Baseline to 1 month</time_frame>
    <description>Skin conductance response (SCR) amplitude measured by placing an electrodermal response transducer on the fore and ring fingers of the participants non-dominant hand, and heart rate (HR) was collected by placing a photoelectric pulse plethysmogram transducer on the middle finger of the participants non-dominant hand, during the presentation of emotionally valent stimuli (positive, negative, neutral, and smoking-related pictures). A single value was estimated by averaging within the specific time interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Response</measure>
    <time_frame>Baseline to 1 month</time_frame>
    <description>Heart Rate Response. A single value was estimated by averaging within the specific time interval. During a quit attempt, smokers were evaluated on how they react to smoking related cues. An interaction term was then formed by the reactivity to smoking stimulus and genotype.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">646</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bupropion starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Varenicline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Varenicline starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo by mouth for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)</description>
    <arm_group_label>Bupropion</arm_group_label>
    <other_name>Wellbutrin</other_name>
    <other_name>Wellbutrin SR</other_name>
    <other_name>Zyban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)</description>
    <arm_group_label>Varenicline</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo by mouth for 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Smoking Cessation Counseling</intervention_name>
    <description>Counseling over 8 months and telephone support calls.</description>
    <arm_group_label>Bupropion</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Varenicline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 18-65 years old&#xD;
&#xD;
          2. Smoking: &gt;/= 5 cigarettes per day within the 2 months preceding the screening visit&#xD;
             and expired CO greater than or equal to 6 ppm.&#xD;
&#xD;
          3. Able to follow verbal and written instructions in English and complete all aspects of&#xD;
             the study&#xD;
&#xD;
          4. Have an address and home telephone number where they may be reached&#xD;
&#xD;
          5. Provide informed consent and agree to all assessments and study procedures&#xD;
&#xD;
          6. Be the only participant in their household&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Within the month immediately preceding the screening visit; use of any form of tobacco&#xD;
             product other than cigarettes on 3 or more days within a week only if the individual&#xD;
             refuses to refrain from non-cigarette tobacco use during the course of this study&#xD;
&#xD;
          2. Within the month immediately preceding the screening visit; use of marijuana in any&#xD;
             form on 3 or more days within a week&#xD;
&#xD;
          3. Within the two weeks immediately preceding the screening visit, involvement on more&#xD;
             than 3 days in any formal smoking cessation activities&#xD;
&#xD;
          4. Current visual or auditory problems that in the opinion of the investigator would&#xD;
             interfere with the completion of study assessments&#xD;
&#xD;
          5. Treatment on a continuous basis within 2 weeks before the screening visit: any&#xD;
             contraindicated medication for Varenicline or Bupropion.&#xD;
&#xD;
          6. Uncontrolled hypertension or other major contraindications for Bupropion or&#xD;
             Varenicline.&#xD;
&#xD;
          7. Severe renal impairment (CR Clearance &lt;30 ml/min/1.73 m2).&#xD;
&#xD;
          8. Laboratory evaluations outside normal limits and of potential clinical significance in&#xD;
             the opinion of the investigator&#xD;
&#xD;
          9. Meet current criteria for psychiatric disorders or substance abuse as assessed by the&#xD;
             MINI for items A, B, D, I, J, K, L, M and N, including a past manic or hypomanic&#xD;
             episode as well as a lifetime psychotic disorder.&#xD;
&#xD;
         10. Subject rated as moderate to high on suicidality as assessed by the MINI.&#xD;
&#xD;
         11. Psychiatric hospitalization within 1 year of screening date.&#xD;
&#xD;
         12. A positive urine pregnancy test during the screening period. Women who are two years&#xD;
             post menopausal, one year post-tubal ligation, or who have had a partial or full&#xD;
             hysterectomy will not be subject to a urine pregnancy test.&#xD;
&#xD;
         13. Pregnant, breast-feeding, or of childbearing potential who is not protected by a&#xD;
             medically acceptable, effective method of birth control while enrolled in the study&#xD;
&#xD;
         14. Use of Varenicline or Bupropion within two weeks before the screening visit.&#xD;
&#xD;
         15. History of hypersensitivity or allergic reaction to Varenicline, tricyclic&#xD;
             antidepressant, Bupropion (Wellbutrin, Zyban) or similar chemical classes or any&#xD;
             component of these formulations.&#xD;
&#xD;
         16. Subject considered by the investigator as unsuitable candidate for receipt of an&#xD;
             investigational drug, or unstable to be followed up throughout the entire duration of&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Cinciripini, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <reference>
    <citation>Cui Y, Robinson JD, Versace F, Lam CY, Minnix JA, Karam-Hage M, Dani JA, Kosten TR, Wetter DW, Brown VL, Cinciripini PM. Differential cigarette-related startle cue reactivity among light, moderate, and heavy smokers. Addict Behav. 2012 Aug;37(8):885-9. doi: 10.1016/j.addbeh.2012.02.003. Epub 2012 Feb 15.</citation>
    <PMID>22571920</PMID>
  </reference>
  <reference>
    <citation>Cui Y, Versace F, Engelmann JM, Minnix JA, Robinson JD, Lam CY, Karam-Hage M, Brown VL, Wetter DW, Dani JA, Kosten TR, Cinciripini PM. Alpha oscillations in response to affective and cigarette-related stimuli in smokers. Nicotine Tob Res. 2013 May;15(5):917-24. doi: 10.1093/ntr/nts209. Epub 2012 Oct 11.</citation>
    <PMID>23060019</PMID>
  </reference>
  <reference>
    <citation>Cui Y, Robinson JD, Engelmann JM, Lam CY, Minnix JA, Karam-Hage M, Wetter DW, Dani JA, Kosten TR, Cinciripini PM. Reinforcement sensitivity underlying treatment-seeking smokers' affect, smoking reinforcement motives, and affective responses. Psychol Addict Behav. 2015 Jun;29(2):300-311. doi: 10.1037/adb0000050. Epub 2015 Jan 26.</citation>
    <PMID>25621416</PMID>
  </reference>
  <reference>
    <citation>Cui Y, Engelmann JM, Xian J, Minnix JA, Lam CY, Karam-Hage M, Cinciripini PM, Robinson JD. Pharmacological intervention and abstinence in smokers undergoing cessation treatment: A psychophysiological study. Int J Psychophysiol. 2018 Jan;123:25-34. doi: 10.1016/j.ijpsycho.2017.12.001. Epub 2017 Dec 6.</citation>
    <PMID>29223599</PMID>
  </reference>
  <reference>
    <citation>Minnix JA, Versace F, Robinson JD, Lam CY, Engelmann JM, Cui Y, Brown VL, Cinciripini PM. The late positive potential (LPP) in response to varying types of emotional and cigarette stimuli in smokers: a content comparison. Int J Psychophysiol. 2013 Jul;89(1):18-25. doi: 10.1016/j.ijpsycho.2013.04.019. Epub 2013 May 2.</citation>
    <PMID>23643564</PMID>
  </reference>
  <reference>
    <citation>Robinson JD, Versace F, Lam CY, Minnix JA, Engelmann JM, Cui Y, Karam-Hage M, Shete SS, Tomlinson GE, Chen TT, Wetter DW, Green CE, Cinciripini PM. The CHRNA3 rs578776 Variant is Associated with an Intrinsic Reward Sensitivity Deficit in Smokers. Front Psychiatry. 2013 Sep 23;4:114. doi: 10.3389/fpsyt.2013.00114. eCollection 2013.</citation>
    <PMID>24065931</PMID>
  </reference>
  <reference>
    <citation>Versace F, Minnix JA, Robinson JD, Lam CY, Brown VL, Cinciripini PM. Brain reactivity to emotional, neutral and cigarette-related stimuli in smokers. Addict Biol. 2011 Apr;16(2):296-307. doi: 10.1111/j.1369-1600.2010.00273.x. Epub 2010 Dec 23.</citation>
    <PMID>21182573</PMID>
  </reference>
  <reference>
    <citation>Versace F, Lam CY, Engelmann JM, Robinson JD, Minnix JA, Brown VL, Cinciripini PM. Beyond cue reactivity: blunted brain responses to pleasant stimuli predict long-term smoking abstinence. Addict Biol. 2012 Nov;17(6):991-1000. doi: 10.1111/j.1369-1600.2011.00372.x. Epub 2011 Oct 4.</citation>
    <PMID>21967530</PMID>
  </reference>
  <reference>
    <citation>Versace F, Engelmann JM, Robinson JD, Jackson EF, Green CE, Lam CY, Minnix JA, Karam-Hage MA, Brown VL, Wetter DW, Cinciripini PM. Prequit fMRI responses to pleasant cues and cigarette-related cues predict smoking cessation outcome. Nicotine Tob Res. 2014 Jun;16(6):697-708. doi: 10.1093/ntr/ntt214. Epub 2013 Dec 27.</citation>
    <PMID>24376278</PMID>
  </reference>
  <reference>
    <citation>Meyer MJ, Coull BA, Versace F, Cinciripini P, Morris JS. Bayesian function-on-function regression for multilevel functional data. Biometrics. 2015 Sep;71(3):563-74. doi: 10.1111/biom.12299. Epub 2015 Mar 18.</citation>
    <PMID>25787146</PMID>
  </reference>
  <reference>
    <citation>Zhu H, Versace F, Cinciripini PM, Rausch P, Morris JS. Robust and Gaussian spatial functional regression models for analysis of event-related potentials. Neuroimage. 2018 Nov 1;181:501-512. doi: 10.1016/j.neuroimage.2018.07.006. Epub 2018 Jul 6.</citation>
    <PMID>30057352</PMID>
  </reference>
  <reference>
    <citation>Cinciripini PM, Green CE, Robinson JD, Karam-Hage M, Engelmann JM, Minnix JA, Wetter DW, Versace F. Benefits of varenicline vs. bupropion for smoking cessation: a Bayesian analysis of the interaction of reward sensitivity and treatment. Psychopharmacology (Berl). 2017 Jun;234(11):1769-1779. doi: 10.1007/s00213-017-4580-2. Epub 2017 Mar 8.</citation>
    <PMID>28275830</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 25, 2007</study_first_submitted>
  <study_first_submitted_qc>July 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2007</study_first_posted>
  <results_first_submitted>December 18, 2020</results_first_submitted>
  <results_first_submitted_qc>April 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 6, 2021</results_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacogenetics</keyword>
  <keyword>Emotional Reactivity</keyword>
  <keyword>Smoking Cessation Counseling</keyword>
  <keyword>Smoking</keyword>
  <keyword>Bupropion</keyword>
  <keyword>Wellbutrin</keyword>
  <keyword>Wellbutrin SR</keyword>
  <keyword>Zyban</keyword>
  <keyword>Varenicline</keyword>
  <keyword>Chantix</keyword>
  <keyword>Placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 24, 2004</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT00507728/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 254 subjects were randomized (varenicline: 75; bupropion: 89; placebo: 90 between December 2005 through October 2010. All subjects were residing in the Greater Houston Area and the study was completed at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>646 participants signed consent, 392 were screen failures</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Varenicline</title>
          <description>Varenicline starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter).&#xD;
Varenicline: Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)</description>
        </group>
        <group group_id="P2">
          <title>Bupropion</title>
          <description>Bupropion starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter).&#xD;
Bupropion: Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo by mouth for 12 weeks.&#xD;
Placebo: Placebo by mouth for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomization to Month 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>From 3 Months to 6 Months</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis dataset is comprised of all treated participants, i.e. Intention to Treat.</population>
      <group_list>
        <group group_id="B1">
          <title>Varenicline</title>
          <description>Varenicline starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter).&#xD;
Varenicline: Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)</description>
        </group>
        <group group_id="B2">
          <title>Bupropion</title>
          <description>Bupropion starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter).&#xD;
Bupropion: Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo by mouth for 12 weeks.&#xD;
Placebo: Placebo by mouth for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="89"/>
            <count group_id="B3" value="90"/>
            <count group_id="B4" value="254"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.5" spread="10.8"/>
                    <measurement group_id="B2" value="44.5" spread="9.3"/>
                    <measurement group_id="B3" value="45.7" spread="10.9"/>
                    <measurement group_id="B4" value="44.6" spread="10.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="225"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="156"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Demographic and individual-level characteristics Wisconsin Smoking Withdrawal Scale (WSWS)</title>
          <description>The Wisconsin Withdrawal Scale (WSWS) contains 7 factors: Anger, Anxiety, Sadness, Concentration, Craving, Sleep, and Hunger. WSWS consists of 28 items that are scored on a 5-point Likert type scale (0 = strongly disagree, 4 = strongly agree). Higher values, of all scales, represent worse outcomes</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>WSWS Anger Subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.8" spread="2.6"/>
                    <measurement group_id="B2" value="4.2" spread="2.7"/>
                    <measurement group_id="B3" value="4.2" spread="7.9"/>
                    <measurement group_id="B4" value="4.1" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WSWS Anxiety Subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.3" spread="2.7"/>
                    <measurement group_id="B2" value="7.3" spread="3.2"/>
                    <measurement group_id="B3" value="7.9" spread="3.3"/>
                    <measurement group_id="B4" value="7.5" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WSWS Concentration Subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.7" spread="1.9"/>
                    <measurement group_id="B2" value="4" spread="2.2"/>
                    <measurement group_id="B3" value="3.9" spread="2.2"/>
                    <measurement group_id="B4" value="3.9" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WSWS Craving Subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.7" spread="3.1"/>
                    <measurement group_id="B2" value="9.4" spread="2.8"/>
                    <measurement group_id="B3" value="9.1" spread="2.6"/>
                    <measurement group_id="B4" value="9.1" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WSWS Hunger Subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.6" spread="3.7"/>
                    <measurement group_id="B2" value="9.8" spread="3.3"/>
                    <measurement group_id="B3" value="11.2" spread="3.7"/>
                    <measurement group_id="B4" value="10.2" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WSWS Sadness Subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.6" spread="2.5"/>
                    <measurement group_id="B2" value="4.2" spread="2.4"/>
                    <measurement group_id="B3" value="4.7" spread="2.5"/>
                    <measurement group_id="B4" value="4.5" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WSWS Sleep Subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.7" spread="4.3"/>
                    <measurement group_id="B2" value="9.3" spread="4.5"/>
                    <measurement group_id="B3" value="8.6" spread="4.4"/>
                    <measurement group_id="B4" value="8.6" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Demographic and individual-level characteristics -Positive and Negative Affect Scales (PANAS)</title>
          <description>The Positive and Negative Affect Schedule (PANAS) is a self-report questionnaire to measure both positive and negative affect. Each item is rated on a 5-point scale of 1 (not at all) to 5 (very much). Scores can range from 10-50 for both the Positive and Negative Affect with the lower scores representing lower levels of Positive/Negative Affect and higher scores representing higher levels of Positive/Negative Affect</description>
          <units>Score on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>PANAS Positive Affect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.8" spread="7.1"/>
                    <measurement group_id="B2" value="36.1" spread="5.7"/>
                    <measurement group_id="B3" value="35.8" spread="6.2"/>
                    <measurement group_id="B4" value="35.9" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PANAS Negative Affect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.8" spread="5.1"/>
                    <measurement group_id="B2" value="15.6" spread="6.9"/>
                    <measurement group_id="B3" value="16.4" spread="5.9"/>
                    <measurement group_id="B4" value="15.6" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Demographic and individual-level characteristics - (CESD)</title>
          <description>Center of Epidemiologic Studies Depression Scale (CESD) a 20-item measure that asks caregivers to rate how often over the past week they experienced symptoms associated with depression, such as restless sleep, poor appetite, and feeling lonely. Response options range from 0 to 3 for each item (0 = Rarely or None of the Time, 1 = Some or Little of the Time, 2 = Moderately or Much of the time, 3 = Most or Almost All the Time). Scores range from 0 to 60, with high scores indicating greater depressive symptoms.</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.7" spread="6.1"/>
                    <measurement group_id="B2" value="6.9" spread="6.1"/>
                    <measurement group_id="B3" value="8.1" spread="7.1"/>
                    <measurement group_id="B4" value="7.3" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Demographic and individual-level characteristics -Modified Cigarette Evaluation Questionnaire (mCEQ)</title>
          <description>Modified Cigarette Evaluation Questionnaire (mCEQ). mCEQ Smoking satisfaction: range (1-21); mCEQ Psychological Reward: range(1-35); mCEQ Aversion: range (1-14); mCEQ Enjoyment of Resp.Tract Sens: range (1-7); mCEQ Craving Reduction: range (1-7). For all scales of mCEQ higher scores indicate worse outcomes (greater intensity of smoking effect). Scores of mCEQ Smoking satisfaction, mCEQ psychological reward and mCEQ aversion were summed to create the subscales. mCEQ Enjoyment of Resp Tract Sens and mCEQ Craving Reduction were single items.</description>
          <units>scores on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>mCEQ Smoking Satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.3" spread="1.1"/>
                    <measurement group_id="B2" value="3.9" spread="1.2"/>
                    <measurement group_id="B3" value="4.2" spread="1.2"/>
                    <measurement group_id="B4" value="4.2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mCEQ Psychological Reward</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.1" spread="4.9"/>
                    <measurement group_id="B2" value="3.7" spread="1.1"/>
                    <measurement group_id="B3" value="3.6" spread="1.3"/>
                    <measurement group_id="B4" value="3.8" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mCEQ Aversion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.6" spread="0.8"/>
                    <measurement group_id="B2" value="1.6" spread="0.7"/>
                    <measurement group_id="B3" value="1.5" spread="0.8"/>
                    <measurement group_id="B4" value="1.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mCEQ Enjoyment of Respiratory Tract Sensation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.9" spread="1.5"/>
                    <measurement group_id="B2" value="2.9" spread="1.4"/>
                    <measurement group_id="B3" value="2.9" spread="1.4"/>
                    <measurement group_id="B4" value="2.9" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mCEQ Craving Reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.1" spread="1.5"/>
                    <measurement group_id="B2" value="5.1" spread="1.4"/>
                    <measurement group_id="B3" value="4.9" spread="1.6"/>
                    <measurement group_id="B4" value="5" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Emotional Reactivity By Pharmacotherapy</title>
        <description>Emotional reactivity measured by the peak eye blink electromyography (EMG) of the orbicularis oculi (ORB) muscle responses to acoustic startle probe delivered during the presentation of emotionally valent stimuli (pleasant, unpleasant, neutral, and smoking-related pictures). A single value was estimated by averaging within the specific time interval.</description>
        <time_frame>Baseline to 1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>Varenicline starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter).&#xD;
Varenicline: Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)</description>
          </group>
          <group group_id="O2">
            <title>Bupropion</title>
            <description>Bupropion starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter).&#xD;
Bupropion: Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo by mouth for 12 weeks.&#xD;
Placebo: Placebo by mouth for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Emotional Reactivity By Pharmacotherapy</title>
          <description>Emotional reactivity measured by the peak eye blink electromyography (EMG) of the orbicularis oculi (ORB) muscle responses to acoustic startle probe delivered during the presentation of emotionally valent stimuli (pleasant, unpleasant, neutral, and smoking-related pictures). A single value was estimated by averaging within the specific time interval.</description>
          <units>microvolts</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Emotional Reactivity (ORB) to Cigarette Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.6" lower_limit="62.3" upper_limit="71.1"/>
                    <measurement group_id="O2" value="64.7" lower_limit="60.9" upper_limit="68.5"/>
                    <measurement group_id="O3" value="65.6" lower_limit="61.5" upper_limit="69.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Reactivity (ORB) to Negative Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.9" lower_limit="66.4" upper_limit="75.4"/>
                    <measurement group_id="O2" value="73.1" lower_limit="69.2" upper_limit="76.9"/>
                    <measurement group_id="O3" value="65.6" lower_limit="61.5" upper_limit="69.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Reactivity (ORB) to Positive Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="62.5" upper_limit="70.9"/>
                    <measurement group_id="O2" value="65.4" lower_limit="61.8" upper_limit="68.9"/>
                    <measurement group_id="O3" value="64.7" lower_limit="60.8" upper_limit="68.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Reactivity (ORB) to Neutral Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.6" lower_limit="45.2" upper_limit="74.1"/>
                    <measurement group_id="O2" value="64.9" lower_limit="52.7" upper_limit="77.2"/>
                    <measurement group_id="O3" value="72.5" lower_limit="59.3" upper_limit="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Emotional Reactivity By Pharmacotherapy Moderated by DRD2 A1 Allele</title>
        <description>The emotional reactivity (ORB EMG) of smokers during cessation will be moderated by genotype. A single value was estimated by averaging within the specific time interval. During a quit attempt, smokers were evaluated on how they react to smoking related cues. An interaction term was then formed by the reactivity to smoking stimulus and genotype.</description>
        <time_frame>Baseline to 1 month</time_frame>
        <population>13 participants had missing data in DRD2 A1 and were not included in the analysis. 1 participant was from the Varenicline group, 7 from the Buproprion group and 5 from the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline w/o DRD2 A1 Allele</title>
            <description>Subjects in the Varenicline group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O2">
            <title>Varenicline With DRD2 A1 Allele</title>
            <description>Subjects in the Varenicline group carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O3">
            <title>Bupropion w/o DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O4">
            <title>Bupropion With DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O5">
            <title>Placebo w/o DRD2 A1 Allele</title>
            <description>Subjects in the Placebo group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O6">
            <title>Placebo With DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group carrying the DRD2 A1 allele</description>
          </group>
        </group_list>
        <measure>
          <title>Emotional Reactivity By Pharmacotherapy Moderated by DRD2 A1 Allele</title>
          <description>The emotional reactivity (ORB EMG) of smokers during cessation will be moderated by genotype. A single value was estimated by averaging within the specific time interval. During a quit attempt, smokers were evaluated on how they react to smoking related cues. An interaction term was then formed by the reactivity to smoking stimulus and genotype.</description>
          <population>13 participants had missing data in DRD2 A1 and were not included in the analysis. 1 participant was from the Varenicline group, 7 from the Buproprion group and 5 from the placebo group.</population>
          <units>microvolts</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Emotional Reactivity (ORB) to Cigarette Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.5" lower_limit="61.1" upper_limit="71.9"/>
                    <measurement group_id="O2" value="69.9" lower_limit="62.8" upper_limit="77.0"/>
                    <measurement group_id="O3" value="66.2" lower_limit="60.4" upper_limit="72"/>
                    <measurement group_id="O4" value="66" lower_limit="60.9" upper_limit="71.2"/>
                    <measurement group_id="O5" value="67.3" lower_limit="61.5" upper_limit="73.1"/>
                    <measurement group_id="O6" value="68.1" lower_limit="62.2" upper_limit="73.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Reactivity (ORB) to Negative Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5" lower_limit="65" upper_limit="75.9"/>
                    <measurement group_id="O2" value="75.1" lower_limit="67.9" upper_limit="82.2"/>
                    <measurement group_id="O3" value="78.6" lower_limit="72.8" upper_limit="84.4"/>
                    <measurement group_id="O4" value="71.3" lower_limit="66.2" upper_limit="76.5"/>
                    <measurement group_id="O5" value="74" lower_limit="68.2" upper_limit="79.7"/>
                    <measurement group_id="O6" value="68.1" lower_limit="62.2" upper_limit="73.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Reactivity (ORB) to Positive Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.5" lower_limit="60.4" upper_limit="70.6"/>
                    <measurement group_id="O2" value="72" lower_limit="65.3" upper_limit="78.7"/>
                    <measurement group_id="O3" value="71.3" lower_limit="65.8" upper_limit="76.7"/>
                    <measurement group_id="O4" value="63.3" lower_limit="58.4" upper_limit="681."/>
                    <measurement group_id="O5" value="68.5" lower_limit="63.1" upper_limit="74"/>
                    <measurement group_id="O6" value="63.8" lower_limit="58.3" upper_limit="69.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Reactivity (ORB) to Neutral Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3" lower_limit="37.4" upper_limit="73.2"/>
                    <measurement group_id="O2" value="67.2" lower_limit="43" upper_limit="91.5"/>
                    <measurement group_id="O3" value="73.9" lower_limit="54.6" upper_limit="93.1"/>
                    <measurement group_id="O4" value="61.2" lower_limit="44" upper_limit="78.3"/>
                    <measurement group_id="O5" value="79.7" lower_limit="61" upper_limit="98.5"/>
                    <measurement group_id="O6" value="67.8" lower_limit="48.3" upper_limit="87.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Smoking Abstinence at 3 Months</title>
        <description>Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking.</description>
        <time_frame>Baseline to 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>Varenicline starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter).&#xD;
Varenicline: Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)</description>
          </group>
          <group group_id="O2">
            <title>Bupropion</title>
            <description>Bupropion starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter).&#xD;
Bupropion: Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo by mouth for 12 weeks.&#xD;
Placebo: Placebo by mouth for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Smoking Abstinence at 3 Months</title>
          <description>Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking.</description>
          <units>probability</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Emotional Reactivity (ORB) to Cigarette Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.003" lower_limit="-0.0777" upper_limit="0.072"/>
                    <measurement group_id="O2" value="-0.01" lower_limit="-0.084" upper_limit="0.065"/>
                    <measurement group_id="O3" value="-0.008" lower_limit="-0.096" upper_limit="0.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Reactivity (ORB) to Negative Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.004" lower_limit="-0.081" upper_limit="0.073"/>
                    <measurement group_id="O2" value="-0.009" lower_limit="-0.076" upper_limit="0.058"/>
                    <measurement group_id="O3" value="-0.007" lower_limit="-0.088" upper_limit="0.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Reactivity (ORB) to Positive Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.003" lower_limit="-0.081" upper_limit="0.076"/>
                    <measurement group_id="O2" value="-0.01" lower_limit="-0.084" upper_limit="0.064"/>
                    <measurement group_id="O3" value="-0.007" lower_limit="-0.092" upper_limit="0.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Reactivity (ORB) to Neutral Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.004" lower_limit="-0.085" upper_limit="0.076"/>
                    <measurement group_id="O2" value="-0.008" lower_limit="-0.084" upper_limit="0.068"/>
                    <measurement group_id="O3" value="-0.007" lower_limit="-0.088" upper_limit="0.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Smoking Abstinence at 3 Months by DRD2 A1 Allele</title>
        <description>Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking.</description>
        <time_frame>Baseline to 3 Month</time_frame>
        <population>13 participants had missing data in DRD2 A1 and were not included in the analysis. 1 participant was from the Varenicline group, 7 from the Buproprion group and 5 from the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline w/o DRD2 A1 Allele</title>
            <description>Subjects in the Varenicline group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O2">
            <title>Varenicline With DRD2 A1 Allele</title>
            <description>Subjects in the Varenicline group carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O3">
            <title>Bupropion w/o DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O4">
            <title>Bupropion With DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O5">
            <title>Placebo w/o DRD2 A1 Allele</title>
            <description>Subjects in the Placebo group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O6">
            <title>Placebo With DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group carrying the DRD2 A1 allele</description>
          </group>
        </group_list>
        <measure>
          <title>Smoking Abstinence at 3 Months by DRD2 A1 Allele</title>
          <description>Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking.</description>
          <population>13 participants had missing data in DRD2 A1 and were not included in the analysis. 1 participant was from the Varenicline group, 7 from the Buproprion group and 5 from the placebo group.</population>
          <units>probability</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Emotional Reactivity (ORB) to Cigarette Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001" lower_limit="-0.002" upper_limit="0.004"/>
                    <measurement group_id="O2" value="-0.004" lower_limit="-0.008" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="-0.003" upper_limit="0.003"/>
                    <measurement group_id="O4" value="-0.003" lower_limit="-0.006" upper_limit="0.001"/>
                    <measurement group_id="O5" value="-0.001" lower_limit="-0.003" upper_limit="0.001"/>
                    <measurement group_id="O6" value="-0.004" lower_limit="-0.008" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Reactivity (ORB) to Negative Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002" lower_limit="-0.002" upper_limit="0.005"/>
                    <measurement group_id="O2" value="-0.005" lower_limit="-0.008" upper_limit="-0.001"/>
                    <measurement group_id="O3" value="0" lower_limit="-0.002" upper_limit="0.002"/>
                    <measurement group_id="O4" value="-0.004" lower_limit="-0.007" upper_limit="0.001"/>
                    <measurement group_id="O5" value="-0.001" lower_limit="-0.003" upper_limit="0.001"/>
                    <measurement group_id="O6" value="-0.004" lower_limit="-0.008" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Reactivity (ORB) to Positive Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001" lower_limit="-0.002" upper_limit="0.005"/>
                    <measurement group_id="O2" value="-0.005" lower_limit="-0.009" upper_limit="-0.001"/>
                    <measurement group_id="O3" value="0" lower_limit="-0.003" upper_limit="0.002"/>
                    <measurement group_id="O4" value="-0.003" lower_limit="-0.006" upper_limit="0"/>
                    <measurement group_id="O5" value="-0.001" lower_limit="-0.003" upper_limit="0.001"/>
                    <measurement group_id="O6" value="-0.004" lower_limit="-0.007" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Reactivity (ORB) to Neutral Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001" lower_limit="-0.002" upper_limit="0.005"/>
                    <measurement group_id="O2" value="-0.005" lower_limit="-0.009" upper_limit="-0.001"/>
                    <measurement group_id="O3" value="0.001" lower_limit="-0.002" upper_limit="0.003"/>
                    <measurement group_id="O4" value="-0.002" lower_limit="-0.005" upper_limit="0.001"/>
                    <measurement group_id="O5" value="-0.001" lower_limit="-0.003" upper_limit="0.001"/>
                    <measurement group_id="O6" value="-0.003" lower_limit="-0.007" upper_limit="0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Smoking Abstinence at 6 Months</title>
        <description>Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking.</description>
        <time_frame>Abstinence at 6 Months ( the effects shown are the increase/decrease in probability of abstinence for 1 unit increase in the predictor)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>Varenicline starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter).&#xD;
Varenicline: Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)</description>
          </group>
          <group group_id="O2">
            <title>Bupropion</title>
            <description>Bupropion starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter).&#xD;
Bupropion: Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo by mouth for 12 weeks.&#xD;
Placebo: Placebo by mouth for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Smoking Abstinence at 6 Months</title>
          <description>Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking.</description>
          <units>probability</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Emotional Reactivity (ORB) to Cigaretee Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007" lower_limit="-0.067" upper_limit="0.082"/>
                    <measurement group_id="O2" value="-0.002" lower_limit="-0.073" upper_limit="0.069"/>
                    <measurement group_id="O3" value="-0.006" lower_limit="-0.091" upper_limit="0.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Reactivity (ORB) to Negative Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008" lower_limit="-0.069" upper_limit="0.085"/>
                    <measurement group_id="O2" value="-0.003" lower_limit="-0.067" upper_limit="0.062"/>
                    <measurement group_id="O3" value="-0.005" lower_limit="-0.081" upper_limit="0.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Reactivity (ORB) to Positive Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" lower_limit="-0.065" upper_limit="0.086"/>
                    <measurement group_id="O2" value="-0.003" lower_limit="-0.075" upper_limit="0.068"/>
                    <measurement group_id="O3" value="-0.005" lower_limit="-0.087" upper_limit="0.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Reactivity (ORB) to Neutral Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008" lower_limit="-0.071" upper_limit="0.087"/>
                    <measurement group_id="O2" value="-0.001" lower_limit="-0.078" upper_limit="0.076"/>
                    <measurement group_id="O3" value="-0.005" lower_limit="-0.052" upper_limit="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Abstinence at 6 Months by DRD2 A1 Allele</title>
        <description>Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking.</description>
        <time_frame>Baseline to 6 Month ( the effects shown are the increase/decrease in probability of abstinence for 1 unit increase in the predictor)</time_frame>
        <population>13 participants had missing data in DRD2 A1 and were not included in the analysis. 1 participant was from the Varenicline group, 7 from the Buproprion group and 5 from the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline w/o DRD2 A1 Allele</title>
            <description>Subjects in the Varenicline group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O2">
            <title>Varenicline With DRD2 A1 Allele</title>
            <description>Subjects in the Varenicline group carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O3">
            <title>Bupropion w/o DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O4">
            <title>Bupropion With DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O5">
            <title>Placebo w/o DRD2 A1 Allele</title>
            <description>Subjects in the Placebo group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O6">
            <title>Placebo With DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group carrying the DRD2 A1 allele</description>
          </group>
        </group_list>
        <measure>
          <title>Abstinence at 6 Months by DRD2 A1 Allele</title>
          <description>Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking.</description>
          <population>13 participants had missing data in DRD2 A1 and were not included in the analysis. 1 participant was from the Varenicline group, 7 from the Buproprion group and 5 from the placebo group.</population>
          <units>probability</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Emotional Reactivity (ORB) to Cigarette Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" lower_limit="0" upper_limit="0.005"/>
                    <measurement group_id="O2" value="-0.001" lower_limit="-0.005" upper_limit="0.003"/>
                    <measurement group_id="O3" value="0.001" lower_limit="-0.002" upper_limit="0.003"/>
                    <measurement group_id="O4" value="-0.001" lower_limit="-0.004" upper_limit="0.002"/>
                    <measurement group_id="O5" value="0" lower_limit="-0.002" upper_limit="0.001"/>
                    <measurement group_id="O6" value="-0.005" lower_limit="-0.01" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Reactivity (ORB) to Negative Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" lower_limit="0.001" upper_limit="0.005"/>
                    <measurement group_id="O2" value="-0.001" lower_limit="-0.005" upper_limit="0.003"/>
                    <measurement group_id="O3" value="0.001" lower_limit="-0.001" upper_limit="0.003"/>
                    <measurement group_id="O4" value="-0.002" lower_limit="-0.005" upper_limit="0.001"/>
                    <measurement group_id="O5" value="0" lower_limit="-0.002" upper_limit="0.001"/>
                    <measurement group_id="O6" value="-0.004" lower_limit="-0.008" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Reactivity (ORB) to Positive Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" lower_limit="0.001" upper_limit="0.006"/>
                    <measurement group_id="O2" value="0" lower_limit="-0.005" upper_limit="0.004"/>
                    <measurement group_id="O3" value="0" lower_limit="-0.002" upper_limit="0.003"/>
                    <measurement group_id="O4" value="-0.001" lower_limit="-0.004" upper_limit="0.002"/>
                    <measurement group_id="O5" value="0" lower_limit="-0.002" upper_limit="0.002"/>
                    <measurement group_id="O6" value="-0.004" lower_limit="-0.008" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Reactivity (ORB) to Neutral Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" lower_limit="0" upper_limit="0.005"/>
                    <measurement group_id="O2" value="-0.001" lower_limit="-0.005" upper_limit="0.003"/>
                    <measurement group_id="O3" value="0.001" lower_limit="-0.002" upper_limit="0.004"/>
                    <measurement group_id="O4" value="-0.001" lower_limit="-0.004" upper_limit="0.002"/>
                    <measurement group_id="O5" value="0" lower_limit="-0.002" upper_limit="0.001"/>
                    <measurement group_id="O6" value="-0.004" lower_limit="-0.009" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptoms of Nicotine Withdrawal Using the Wisconsin Smoking Withdrawal Scale (WSWS)</title>
        <description>Symptoms of nicotine withdrawal measured using Wisconsin Smoking Withdrawal Scale (WSWS). The Wisconsin Withdrawal Scale (WSWS) contains 7 factors: Anger, Anxiety, Sadness, Concentration, Craving, Sleep, and Hunger. WSWS consists of 28 items that are scored on a 5-point Likert type scale (0 = strongly disagree, 4 = strongly agree). A single value was estimated by averaging within the specific time interval. Higher values represent worse outcome. The average value was estimated from Baseline to 8 months</description>
        <time_frame>Baseline to 8 months</time_frame>
        <population>13 participants had missing data in DRD2 A1 and were not included in the analysis. 1 participant was from the Varenicline group, 7 from the Buproprion group and 5 from the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline w/o DRD2 A1 Allele</title>
            <description>Subjects in the Varenicline group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O2">
            <title>Varenicline With DRD2 A1 Allele</title>
            <description>Subjects in the Varenicline group carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O3">
            <title>Bupropion w/o DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O4">
            <title>Bupropion With DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O5">
            <title>Placebo w/o DRD2 A1 Allele</title>
            <description>Subjects in the Placebo group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O6">
            <title>Placebo With DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group carrying the DRD2 A1 allele</description>
          </group>
        </group_list>
        <measure>
          <title>Symptoms of Nicotine Withdrawal Using the Wisconsin Smoking Withdrawal Scale (WSWS)</title>
          <description>Symptoms of nicotine withdrawal measured using Wisconsin Smoking Withdrawal Scale (WSWS). The Wisconsin Withdrawal Scale (WSWS) contains 7 factors: Anger, Anxiety, Sadness, Concentration, Craving, Sleep, and Hunger. WSWS consists of 28 items that are scored on a 5-point Likert type scale (0 = strongly disagree, 4 = strongly agree). A single value was estimated by averaging within the specific time interval. Higher values represent worse outcome. The average value was estimated from Baseline to 8 months</description>
          <population>13 participants had missing data in DRD2 A1 and were not included in the analysis. 1 participant was from the Varenicline group, 7 from the Buproprion group and 5 from the placebo group.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anger</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.394" lower_limit="3.629" upper_limit="5.159"/>
                    <measurement group_id="O2" value="4.222" lower_limit="3.152" upper_limit="5.291"/>
                    <measurement group_id="O3" value="4.28" lower_limit="3.402" upper_limit="5.157"/>
                    <measurement group_id="O4" value="4.41" lower_limit="3.59" upper_limit="5.23"/>
                    <measurement group_id="O5" value="5.584" lower_limit="4.744" upper_limit="6.424"/>
                    <measurement group_id="O6" value="5.752" lower_limit="4.884" upper_limit="6.621"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.218" lower_limit="5.384" upper_limit="7.052"/>
                    <measurement group_id="O2" value="5.873" lower_limit="4.707" upper_limit="7.038"/>
                    <measurement group_id="O3" value="6.587" lower_limit="5.63" upper_limit="7.543"/>
                    <measurement group_id="O4" value="6.587" lower_limit="5.63" upper_limit="7.543"/>
                    <measurement group_id="O5" value="7.785" lower_limit="6.87" upper_limit="8.7"/>
                    <measurement group_id="O6" value="7.915" lower_limit="6.968" upper_limit="8.862"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.743" lower_limit="3.117" upper_limit="4.369"/>
                    <measurement group_id="O2" value="3.407" lower_limit="2.531" upper_limit="4.282"/>
                    <measurement group_id="O3" value="4.238" lower_limit="3.521" upper_limit="4.956"/>
                    <measurement group_id="O4" value="3.935" lower_limit="3.265" upper_limit="4.605"/>
                    <measurement group_id="O5" value="4.764" lower_limit="4.077" upper_limit="5.451"/>
                    <measurement group_id="O6" value="4.951" lower_limit="4.242" upper_limit="5.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craving</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.646" lower_limit="5.591" upper_limit="7.701"/>
                    <measurement group_id="O2" value="6.252" lower_limit="4.777" upper_limit="7.726"/>
                    <measurement group_id="O3" value="6.814" lower_limit="5.605" upper_limit="8.024"/>
                    <measurement group_id="O4" value="6.78" lower_limit="5.651" upper_limit="7.91"/>
                    <measurement group_id="O5" value="9.024" lower_limit="7.866" upper_limit="10.181"/>
                    <measurement group_id="O6" value="8.696" lower_limit="7.499" upper_limit="9.893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hunger</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.016" lower_limit="10.09" upper_limit="11.942"/>
                    <measurement group_id="O2" value="10.707" lower_limit="9.413" upper_limit="12.001"/>
                    <measurement group_id="O3" value="9.79" lower_limit="8.729" upper_limit="10.852"/>
                    <measurement group_id="O4" value="11.082" lower_limit="10.09" upper_limit="12.074"/>
                    <measurement group_id="O5" value="11.207" lower_limit="10.19" upper_limit="12.223"/>
                    <measurement group_id="O6" value="11.044" lower_limit="9.994" upper_limit="12.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sadness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.246" lower_limit="3.535" upper_limit="4.958"/>
                    <measurement group_id="O2" value="3.738" lower_limit="2.744" upper_limit="4.732"/>
                    <measurement group_id="O3" value="4.005" lower_limit="3.189" upper_limit="4.82"/>
                    <measurement group_id="O4" value="4.338" lower_limit="3.577" upper_limit="5.1"/>
                    <measurement group_id="O5" value="5.293" lower_limit="4.513" upper_limit="6.074"/>
                    <measurement group_id="O6" value="5.865" lower_limit="5.057" upper_limit="6.673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.721" lower_limit="6.494" upper_limit="8.948"/>
                    <measurement group_id="O2" value="8.153" lower_limit="6.438" upper_limit="9.868"/>
                    <measurement group_id="O3" value="9.672" lower_limit="8.265" upper_limit="11.079"/>
                    <measurement group_id="O4" value="9.528" lower_limit="8.214" upper_limit="10.843"/>
                    <measurement group_id="O5" value="9.078" lower_limit="7.731" upper_limit="10.424"/>
                    <measurement group_id="O6" value="8.629" lower_limit="7.236" upper_limit="10.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptoms of Nicotine Withdrawal and Negative Affect Using Positive and Negative Affect Scale (PANAS)</title>
        <description>Symptoms of nicotine withdrawal and negative affect were measured using the Positive and Negative Affect Scale (PANAS). The Positive and Negative Affect Schedule (PANAS) is a self-report questionnaire to measure both positive and negative affect. Each item is rated on a 5-point scale of 1 (not at all) to 5 (very much). Scores can range from 10-50 for both the Positive and Negative Affect with the lower scores representing lower levels of Positive/Negative Affect and higher scores representing higher levels of Positive/Negative Affect. The average value was estimated from Baseline to 8 months</description>
        <time_frame>Baseline to 8 months</time_frame>
        <population>13 participants had missing data in DRD2 A1 and were not included in the analysis. 1 participant was from the Varenicline group, 7 from the Buproprion group and 5 from the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline w/o DRD2 A1 Allele</title>
            <description>Subjects in the Varenicline group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O2">
            <title>Varenicline With DRD2 A1 Allele</title>
            <description>Subjects in the Varenicline group carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O3">
            <title>Bupropion w/o DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O4">
            <title>Bupropion With DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O5">
            <title>Placebo w/o DRD2 A1 Allele</title>
            <description>Subjects in the Placebo group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O6">
            <title>Placebo With DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group carrying the DRD2 A1 allele</description>
          </group>
        </group_list>
        <measure>
          <title>Symptoms of Nicotine Withdrawal and Negative Affect Using Positive and Negative Affect Scale (PANAS)</title>
          <description>Symptoms of nicotine withdrawal and negative affect were measured using the Positive and Negative Affect Scale (PANAS). The Positive and Negative Affect Schedule (PANAS) is a self-report questionnaire to measure both positive and negative affect. Each item is rated on a 5-point scale of 1 (not at all) to 5 (very much). Scores can range from 10-50 for both the Positive and Negative Affect with the lower scores representing lower levels of Positive/Negative Affect and higher scores representing higher levels of Positive/Negative Affect. The average value was estimated from Baseline to 8 months</description>
          <population>13 participants had missing data in DRD2 A1 and were not included in the analysis. 1 participant was from the Varenicline group, 7 from the Buproprion group and 5 from the placebo group.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive Affect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.507" lower_limit="33.494" upper_limit="37.521"/>
                    <measurement group_id="O2" value="37.315" lower_limit="34.5" upper_limit="40.13"/>
                    <measurement group_id="O3" value="36.429" lower_limit="34.122" upper_limit="38.735"/>
                    <measurement group_id="O4" value="35.281" lower_limit="33.125" upper_limit="37.437"/>
                    <measurement group_id="O5" value="33.672" lower_limit="31.463" upper_limit="35.882"/>
                    <measurement group_id="O6" value="33.984" lower_limit="31.709" upper_limit="36.259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Affect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.93" lower_limit="14.404" upper_limit="17.455"/>
                    <measurement group_id="O2" value="14.98" lower_limit="12.849" upper_limit="17.112"/>
                    <measurement group_id="O3" value="15.782" lower_limit="14.032" upper_limit="17.532"/>
                    <measurement group_id="O4" value="16.385" lower_limit="14.751" upper_limit="18.02"/>
                    <measurement group_id="O5" value="18.017" lower_limit="16.343" upper_limit="19.691"/>
                    <measurement group_id="O6" value="18.902" lower_limit="17.166" upper_limit="20.638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptoms of Depression Using the Center for Epidemiologic Studies Depression Scale (CES-D)</title>
        <description>Symptoms of nicotine withdrawal measured using Center for Epidemiologic Studies Depression Scale (CES-D). Center of Epidemiologic Studies Depression Scale (CESD) a 20-item measure that asks caregivers to rate how often over the past week they experienced symptoms associated with depression, such as restless sleep, poor appetite, and feeling lonely. Response options range from 0 to 3 for each item (0 = Rarely or None of the Time, 1 = Some or Little of the Time, 2 = Moderately or Much of the time, 3 = Most or Almost All the Time). Scores range from 0 to 60, with high scores indicating greater depressive symptoms. The average value was estimated from Baseline to 8 months</description>
        <time_frame>Baseline to 8 months</time_frame>
        <population>13 participants had missing data in DRD2 A1 and were not included in the analysis. 1 participant was from the Varenicline group, 7 from the Buproprion group and 5 from the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline w/o DRD2 A1 Allele</title>
            <description>Subjects in the Varenicline group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O2">
            <title>Varenicline With DRD2 A1 Allele</title>
            <description>Subjects in the Varenicline group carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O3">
            <title>Bupropion w/o DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O4">
            <title>Bupropion With DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O5">
            <title>Placebo w/o DRD2 A1 Allele</title>
            <description>Subjects in the Placebo group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O6">
            <title>Placebo With DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group carrying the DRD2 A1 allele</description>
          </group>
        </group_list>
        <measure>
          <title>Symptoms of Depression Using the Center for Epidemiologic Studies Depression Scale (CES-D)</title>
          <description>Symptoms of nicotine withdrawal measured using Center for Epidemiologic Studies Depression Scale (CES-D). Center of Epidemiologic Studies Depression Scale (CESD) a 20-item measure that asks caregivers to rate how often over the past week they experienced symptoms associated with depression, such as restless sleep, poor appetite, and feeling lonely. Response options range from 0 to 3 for each item (0 = Rarely or None of the Time, 1 = Some or Little of the Time, 2 = Moderately or Much of the time, 3 = Most or Almost All the Time). Scores range from 0 to 60, with high scores indicating greater depressive symptoms. The average value was estimated from Baseline to 8 months</description>
          <population>13 participants had missing data in DRD2 A1 and were not included in the analysis. 1 participant was from the Varenicline group, 7 from the Buproprion group and 5 from the placebo group.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.084" lower_limit="6.19" upper_limit="9.978"/>
                    <measurement group_id="O2" value="6.847" lower_limit="4.2" upper_limit="9.494"/>
                    <measurement group_id="O3" value="7.588" lower_limit="5.416" upper_limit="9.76"/>
                    <measurement group_id="O4" value="8.362" lower_limit="6.333" upper_limit="10.39"/>
                    <measurement group_id="O5" value="8.65" lower_limit="6.572" upper_limit="10.729"/>
                    <measurement group_id="O6" value="10.799" lower_limit="8.647" upper_limit="12.951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measures of Smoking Satisfaction and Psychological Reward Using the Modified Cigarette Evaluation Questionnaire (mCEQ) Subscales</title>
        <description>Modified Cigarette Evaluation Questionnaire (mCEQ). mCEQ Smoking satisfaction: range (1-21); mCEQ Psychological Reward: range(1-35); mCEQ Aversion: range (1-14); mCEQ Enjoyment of Resp.Tract Sens: range (1-7); mCEQ Craving Reduction: range (1-7). For all scales of mCEQ higher scores indicate worse outcomes (greater intensity of smoking effect). Scores of mCEQ Smoking satisfaction, mCEQ psychological reward and mCEQ aversion were summed to create the subscales. mCEQ Enjoyment of Resp Tract Sens and mCEQ Craving Reduction were single items.</description>
        <time_frame>Baseline to 8 months</time_frame>
        <population>13 participants had missing data in DRD2 A1 and were not included in the analysis. 1 participant was from the Varenicline group, 7 from the Buproprion group and 5 from the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline w/o DRD2 A1 Allele</title>
            <description>Subjects in the Varenicline group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O2">
            <title>Varenicline With DRD2 A1 Allele</title>
            <description>Subjects in the Varenicline group carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O3">
            <title>Bupropion w/o DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O4">
            <title>Bupropion With DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O5">
            <title>Placebo w/o DRD2 A1 Allele</title>
            <description>Subjects in the Placebo group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O6">
            <title>Placebo With DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group carrying the DRD2 A1 allele</description>
          </group>
        </group_list>
        <measure>
          <title>Measures of Smoking Satisfaction and Psychological Reward Using the Modified Cigarette Evaluation Questionnaire (mCEQ) Subscales</title>
          <description>Modified Cigarette Evaluation Questionnaire (mCEQ). mCEQ Smoking satisfaction: range (1-21); mCEQ Psychological Reward: range(1-35); mCEQ Aversion: range (1-14); mCEQ Enjoyment of Resp.Tract Sens: range (1-7); mCEQ Craving Reduction: range (1-7). For all scales of mCEQ higher scores indicate worse outcomes (greater intensity of smoking effect). Scores of mCEQ Smoking satisfaction, mCEQ psychological reward and mCEQ aversion were summed to create the subscales. mCEQ Enjoyment of Resp Tract Sens and mCEQ Craving Reduction were single items.</description>
          <population>13 participants had missing data in DRD2 A1 and were not included in the analysis. 1 participant was from the Varenicline group, 7 from the Buproprion group and 5 from the placebo group.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Smoking Satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.895" lower_limit="1.912" upper_limit="3.879"/>
                    <measurement group_id="O2" value="2.591" lower_limit="1.253" upper_limit="3.93"/>
                    <measurement group_id="O3" value="4.064" lower_limit="2.94" upper_limit="5.187"/>
                    <measurement group_id="O4" value="3.369" lower_limit="2.135" upper_limit="4.603"/>
                    <measurement group_id="O5" value="3.025" lower_limit="2.087" upper_limit="3.963"/>
                    <measurement group_id="O6" value="3.515" lower_limit="2.368" upper_limit="4.662"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychological Reward</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.819" lower_limit="2.109" upper_limit="3.528"/>
                    <measurement group_id="O2" value="2.155" lower_limit="1.181" upper_limit="3.13"/>
                    <measurement group_id="O3" value="2.519" lower_limit="1.693" upper_limit="3.346"/>
                    <measurement group_id="O4" value="2.723" lower_limit="1.812" upper_limit="3.634"/>
                    <measurement group_id="O5" value="3.575" lower_limit="2.861" upper_limit="4.289"/>
                    <measurement group_id="O6" value="3.246" lower_limit="2.399" upper_limit="4.093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aversion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.612" lower_limit="1.357" upper_limit="1.867"/>
                    <measurement group_id="O2" value="1.694" lower_limit="1.342" upper_limit="2.045"/>
                    <measurement group_id="O3" value="1.988" lower_limit="1.69" upper_limit="2.286"/>
                    <measurement group_id="O4" value="1.79" lower_limit="1.461" upper_limit="2.119"/>
                    <measurement group_id="O5" value="1.808" lower_limit="1.549" upper_limit="2.067"/>
                    <measurement group_id="O6" value="1.69" lower_limit="1.384" upper_limit="1.996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enjoyment of Respiratory Tract Sensation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.912" lower_limit="0.146" upper_limit="3.678"/>
                    <measurement group_id="O2" value="1.703" lower_limit="-0.692" upper_limit="4.099"/>
                    <measurement group_id="O3" value="4.096" lower_limit="2.094" upper_limit="6.099"/>
                    <measurement group_id="O4" value="1.955" lower_limit="-0.243" upper_limit="4.153"/>
                    <measurement group_id="O5" value="3.711" lower_limit="2.048" upper_limit="5.375"/>
                    <measurement group_id="O6" value="2.783" lower_limit="0.741" upper_limit="4.825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craving Reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.531" lower_limit="3.232" upper_limit="5.831"/>
                    <measurement group_id="O2" value="3.952" lower_limit="2.2" upper_limit="5.705"/>
                    <measurement group_id="O3" value="4.564" lower_limit="3.083" upper_limit="6.044"/>
                    <measurement group_id="O4" value="6.628" lower_limit="5.017" upper_limit="8.238"/>
                    <measurement group_id="O5" value="4.486" lower_limit="3.269" upper_limit="5.702"/>
                    <measurement group_id="O6" value="4.673" lower_limit="3.176" upper_limit="6.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Skin Conductance Response</title>
        <description>Skin conductance response (SCR) amplitude measured by placing an electrodermal response transducer on the fore and ring fingers of the participants non-dominant hand, and heart rate (HR) was collected by placing a photoelectric pulse plethysmogram transducer on the middle finger of the participants non-dominant hand, during the presentation of emotionally valent stimuli (positive, negative, neutral, and smoking-related pictures). A single value was estimated by averaging within the specific time interval.</description>
        <time_frame>Baseline to 1 month</time_frame>
        <population>13 participants had missing data in DRD2 A1 and were not included in the analysis. 1 participant was from the Varenicline group, 7 from the Buproprion group and 5 from the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline w/o DRD2 A1 Allele</title>
            <description>Subjects in the Varenicline group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O2">
            <title>Varenicline With DRD2 A1 Allele</title>
            <description>Subjects in the Varenicline group carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O3">
            <title>Bupropion w/o DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O4">
            <title>Bupropion With DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O5">
            <title>Placebo w/o DRD2 A1 Allele</title>
            <description>Subjects in the Placebo group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O6">
            <title>Placebo With DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group carrying the DRD2 A1 allele</description>
          </group>
        </group_list>
        <measure>
          <title>Skin Conductance Response</title>
          <description>Skin conductance response (SCR) amplitude measured by placing an electrodermal response transducer on the fore and ring fingers of the participants non-dominant hand, and heart rate (HR) was collected by placing a photoelectric pulse plethysmogram transducer on the middle finger of the participants non-dominant hand, during the presentation of emotionally valent stimuli (positive, negative, neutral, and smoking-related pictures). A single value was estimated by averaging within the specific time interval.</description>
          <population>13 participants had missing data in DRD2 A1 and were not included in the analysis. 1 participant was from the Varenicline group, 7 from the Buproprion group and 5 from the placebo group.</population>
          <units>Microsiemens</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Skin conductance to Cigarette Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.301" lower_limit="1.619" upper_limit="2.982"/>
                    <measurement group_id="O2" value="2.016" lower_limit="1.132" upper_limit="2.901"/>
                    <measurement group_id="O3" value="2.275" lower_limit="1.512" upper_limit="3.037"/>
                    <measurement group_id="O4" value="1.797" lower_limit="1.082" upper_limit="2.511"/>
                    <measurement group_id="O5" value="2.272" lower_limit="1.54" upper_limit="3.005"/>
                    <measurement group_id="O6" value="2.443" lower_limit="1.703" upper_limit="3.183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin conductance to Negative Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.295" lower_limit="1.613" upper_limit="2.976"/>
                    <measurement group_id="O2" value="1.969" lower_limit="1.084" upper_limit="2.855"/>
                    <measurement group_id="O3" value="2.31" lower_limit="1.547" upper_limit="3.072"/>
                    <measurement group_id="O4" value="1.695" lower_limit="0.999" upper_limit="2.391"/>
                    <measurement group_id="O5" value="2.355" lower_limit="1.611" upper_limit="3.099"/>
                    <measurement group_id="O6" value="2.485" lower_limit="1.756" upper_limit="3.215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin conductance to Positive Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.256" lower_limit="1.58" upper_limit="2.931"/>
                    <measurement group_id="O2" value="1.984" lower_limit="1.106" upper_limit="2.862"/>
                    <measurement group_id="O3" value="2.299" lower_limit="1.542" upper_limit="3.055"/>
                    <measurement group_id="O4" value="1.7" lower_limit="1.01" upper_limit="2.39"/>
                    <measurement group_id="O5" value="2.296" lower_limit="1.569" upper_limit="3.023"/>
                    <measurement group_id="O6" value="2.565" lower_limit="1.831" upper_limit="3.299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin conductance to Neutral Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.261" lower_limit="1.578" upper_limit="2.944"/>
                    <measurement group_id="O2" value="2.017" lower_limit="1.13" upper_limit="2.904"/>
                    <measurement group_id="O3" value="2.369" lower_limit="1.602" upper_limit="3.136"/>
                    <measurement group_id="O4" value="1.699" lower_limit="1.002" upper_limit="2.397"/>
                    <measurement group_id="O5" value="2.362" lower_limit="1.616" upper_limit="3.107"/>
                    <measurement group_id="O6" value="2.559" lower_limit="1.82" upper_limit="3.299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate Response</title>
        <description>Heart Rate Response. A single value was estimated by averaging within the specific time interval. During a quit attempt, smokers were evaluated on how they react to smoking related cues. An interaction term was then formed by the reactivity to smoking stimulus and genotype.</description>
        <time_frame>Baseline to 1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline w/o DRD2 A1 Allele</title>
            <description>Subjects in the Varenicline group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O2">
            <title>Varenicline With DRD2 A1 Allele</title>
            <description>Subjects in the Varenicline group carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O3">
            <title>Bupropion w/o DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O4">
            <title>Bupropion With DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O5">
            <title>Placebo w/o DRD2 A1 Allele</title>
            <description>Subjects in the Placebo group not carrying the DRD2 A1 allele</description>
          </group>
          <group group_id="O6">
            <title>Placebo With DRD2 A1 Allele</title>
            <description>Subjects in the Bupropion group carrying the DRD2 A1 allele</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate Response</title>
          <description>Heart Rate Response. A single value was estimated by averaging within the specific time interval. During a quit attempt, smokers were evaluated on how they react to smoking related cues. An interaction term was then formed by the reactivity to smoking stimulus and genotype.</description>
          <units>beats per minute</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart Rate response to Cigarette Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.731" lower_limit="66.962" upper_limit="72.5"/>
                    <measurement group_id="O2" value="68.652" lower_limit="65.068" upper_limit="72.236"/>
                    <measurement group_id="O3" value="71.427" lower_limit="68.331" upper_limit="74.524"/>
                    <measurement group_id="O4" value="69.836" lower_limit="66.974" upper_limit="72.699"/>
                    <measurement group_id="O5" value="65.966" lower_limit="62.987" upper_limit="68.944"/>
                    <measurement group_id="O6" value="65.276" lower_limit="62.266" upper_limit="68.286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate response to Negative Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.562" lower_limit="66.722" upper_limit="72.402"/>
                    <measurement group_id="O2" value="68.078" lower_limit="64.403" upper_limit="71.753"/>
                    <measurement group_id="O3" value="71.077" lower_limit="67.904" upper_limit="74.25"/>
                    <measurement group_id="O4" value="69.595" lower_limit="66.699" upper_limit="72.492"/>
                    <measurement group_id="O5" value="65.768" lower_limit="62.713" upper_limit="68.823"/>
                    <measurement group_id="O6" value="65.569" lower_limit="62.523" upper_limit="68.615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate response to Positive Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.151" lower_limit="66.351" upper_limit="71.95"/>
                    <measurement group_id="O2" value="68.711" lower_limit="65.087" upper_limit="72.334"/>
                    <measurement group_id="O3" value="71.518" lower_limit="68.386" upper_limit="74.65"/>
                    <measurement group_id="O4" value="70.404" lower_limit="67.546" upper_limit="73.262"/>
                    <measurement group_id="O5" value="65.787" lower_limit="62.776" upper_limit="68.799"/>
                    <measurement group_id="O6" value="65.927" lower_limit="62.929" upper_limit="68.926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate response to Neutral Stimuli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.621" lower_limit="66.798" upper_limit="72.444"/>
                    <measurement group_id="O2" value="68.969" lower_limit="65.315" upper_limit="72.624"/>
                    <measurement group_id="O3" value="71.706" lower_limit="68.546" upper_limit="74.865"/>
                    <measurement group_id="O4" value="70.234" lower_limit="67.351" upper_limit="73.117"/>
                    <measurement group_id="O5" value="65.237" lower_limit="62.2" upper_limit="68.273"/>
                    <measurement group_id="O6" value="66.04" lower_limit="62.981" upper_limit="69.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline, up to 8 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Varenicline</title>
          <description>Varenicline starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter).&#xD;
Varenicline: Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)</description>
        </group>
        <group group_id="E2">
          <title>Bupropion</title>
          <description>Bupropion starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter).&#xD;
Bupropion: Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo by mouth for 12 weeks.&#xD;
Placebo: Placebo by mouth for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Increased Coughing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Tachycardia/Palpita..</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Glucose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>BLOOD IN STOOL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>APPETITE DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>APPETITE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Body odor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>TASTE PERVERSION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Allergy, Seasonal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ACCIDENTAL INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Herniated Disc</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrospinal fluid..</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>PARESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Dreams</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Anxiety Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Elevated mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Emotional liability</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Reduced inhibition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney Stones</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Urine abnormality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Increased Coughing</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>BRUISE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>SWEATING INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul M Cinciripini, MD, Chair, Behavioral Science</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>(713) 745-1868</phone>
      <email>pcinciri@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

